Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients
Evaluation of the Safety and Immunogenicity of Varivax® (Live-Attenuated Varicella-Zoster Virus Vaccine) in Pediatric Renal Transplant Recipients
Sponsor: Cooperative Clinical Trials in Pediatric Transplantation
Terminated
Slow enrollment
Other terminated trials from Cooperative Clinical Trials in Pediatric Transplantation
More terminations from Cooperative Clinical Trials in Pediatric Transplantation
Other Kidney Transplant Recipients trials with similar outcome
Listed as NCT00005009, this PHASE1 trial focuses on Kidney Transplant Recipients and remains terminated or withdrawn. Sponsored by Cooperative Clinical Trials in Pediatric Transplantation, it has been updated 7 times since 1998, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jun 2022 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
Status: Completed → Terminated
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Feb 1998
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cooperative Clinical Trials in Pediatric Transplantation
- Merck Sharp & Dohme LLC
- NIAID Vaccine and Treatment Evaluation Units (VTEUs)
- National Institute of Allergy and Infectious Diseases (NIAID)
- North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS)
For direct contact, visit the study record on ClinicalTrials.gov .